Can Medical Cannabis Effectively Treat Dystonia? 

What We Know So Far 

Dystonia is a neurological movement disorder that causes involuntary muscle contractions, leading to twisting, tremors, or unusual postures. It can affect one or several areas of the body. 

Standard treatment includes botulinum toxin injections, muscle relaxants, and physical therapy. However, some people continue to experience significant discomfort despite these options. 

Recently, medical cannabis, also known as cannabis-based medicinal products (CBMPs), has attracted attention as a potential therapy for neurological disorders. According to NHS guidance, cannabis products are sometimes considered for specific severe conditions, but their use in dystonia remains limited. 

What The Evidence Says 

A 2023 study published in Frontiers in Neurology followed 23 patients with dystonia who used licensed medical cannabis for an average of 2.5 years. Patients with widespread forms of dystonia reported around 63% symptom reduction, compared with 32% for focal dystonia. 

Participants rated pain relief at 3.8/5 and quality of life improvement at 3.6/5. According to the authors, THC-dominant formulations and inhaled cannabis were associated with greater benefit compared with sublingual oils (Frontiers in Neurology, 2023). 

A 2025 systematic review confirmed that while cannabinoids show potential in neurological conditions, evidence for dystonia remains limited and observational. No randomised controlled trials have been published to date (PMC11839665, 2025). 

How THC And CBD May Work 

THC (Tetrahydrocannabinol): 

THC interacts with CB1 receptors in brain regions that control movement, including the basal ganglia. This interaction may reduce excessive nerve activity and help relax muscle contractions. 

CBD (Cannabidiol): 

CBD has a different mechanism, acting on serotonin and TRPV1 receptors. It may help reduce inflammation and anxiety, although its direct role in movement control remains less clear. 

Research indicates that both compounds may work best when balanced in specific ratios, but optimal dosing and formulations for dystonia have not yet been established. 

What NICE And NHS Guidance Recommend 

According to NICE Guidance NG144, cannabis-based medicinal products are recommended only for: 

• Chronic pain (in limited circumstances). 

• Severe treatment-resistant epilepsy. 

• Spasticity associated with multiple sclerosis. 

Dystonia is not an approved indication. 
According to NHS England’s guidance on CBPMs, these medicines may only be prescribed by a specialist doctor on a case-by-case basis. 

NHS advice (updated April 2025) confirms that most prescriptions occur privately through specialists authorised to issue unlicensed medicines (NHS Medical Cannabis Guidance). 

What Patients Report in Real-World Use 

In the 2023 Frontiers in Neurology study, many patients described improvements in comfort, sleep, and mobility. Inhaled THC-dominant products were most frequently associated with positive outcomes. 

However, results vary widely. Some people reported no significant benefit, while others experienced mild or temporary relief. 

These findings are supported by patient data from the UK Medical Cannabis Registry, which shows improved quality of life for some users, though causality remains uncertain. 

What Are the Risks and Uncertainties? 

Like all medicines, medical cannabis carries side effects. The most common include dry mouth, sedation, dizziness, and mood changes. Approximately 13% of patients in the 2023 study discontinued treatment because of side effects or limited benefit. 

Evidence quality remains modest, with most studies relying on small, uncontrolled samples. There are no placebo-controlled trials or validated dystonia rating scales in use. 

Researchers emphasise the need for large-scale, blinded studies to confirm whether these early findings represent genuine therapeutic effects or subjective improvements. 

The Clinical Bottom Line 

• Evidence for cannabis in dystonia is encouraging but low quality. 

• NICE and NHS do not currently recommend CBMPs for dystonia. 

• THC and CBD act differently, and dosing remains unclear. 

• Reported benefits are mostly patient-perceived, not objectively measured. 

• Further controlled trials are essential before wider NHS use. 

Safe Next Steps 

Providers like AlleviMed offer information about eligibility for medical cannabis under existing UK regulations. These services help patients understand how prescribing works through specialist clinics, in line with MHRA and NHS standards.  

Anyone considering medical cannabis for dystonia should consult a qualified specialist before starting treatment. This ensures safety, legality, and ongoing medical supervision. 

Takeaway: What This Means for Patients 

Medical cannabis may ease dystonia symptoms for some people, particularly when other treatments have failed. However, current evidence remains limited and cannot support NHS prescribing at this stage. 

If you are exploring this option, speak with a specialist doctor familiar with unlicensed cannabis medicines. They can explain whether it is appropriate for your symptoms and monitor you safely over time. 

While research continues, the responsible approach is careful, clinician-guided use within UK regulatory frameworks.